Table 3.
Cytotoxicites of compounds 1–12 against five cancer cell lines.
| Compounds | IC50 ± SD (μM) | |||||
|---|---|---|---|---|---|---|
| LN229 | U251 | Capan-2 | HeLa | HepG2 | NHA | |
| 1 | 4.18 ± 0.31 | 3.85 ± 0.44 | 3.26 ± 0.34 | 3.30 ± 0.38 | 4.32 ± 0.51 | >50 |
| 2 | 15.39 ± 0.47 | 15.76 ± 0.65 | 20.37 ± 1.05 | 22.3 ± 1.33 | 18.76 ± 1.25 | >50 |
| 3 | >50 | >50 | >50 | >50 | >50 | >50 |
| 4 | >50 | >50 | >50 | >50 | >50 | >50 |
| 5 | >50 | >50 | >50 | >50 | >50 | >50 |
| 6 | >50 | >50 | >50 | >50 | >50 | >50 |
| 7 | >50 | >50 | >50 | >50 | >50 | >50 |
| 8 | >50 | >50 | >50 | >50 | >50 | >50 |
| 9 | >50 | >50 | >50 | >50 | >50 | >50 |
| 10 | >50 | >50 | >50 | >50 | >50 | >50 |
| 11 | >50 | >50 | >50 | >50 | >50 | >50 |
| 12 | >50 | >50 | >50 | >50 | >50 | >50 |
| Doxorubicin a | 0.35 ± 0.05 | 0.21 ± 0.04 | 0.18 ± 0.02 | 0.18 ± 0.02 | 0.21 ± 0.02 | >50 |
a Positive control.